These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

580 related articles for article (PubMed ID: 25322323)

  • 1. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
    Awad MM; Shaw AT
    Clin Adv Hematol Oncol; 2014 Jul; 12(7):429-39. PubMed ID: 25322323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
    Friboulet L; Li N; Katayama R; Lee CC; Gainor JF; Crystal AS; Michellys PY; Awad MM; Yanagitani N; Kim S; Pferdekamper AC; Li J; Kasibhatla S; Sun F; Sun X; Hua S; McNamara P; Mahmood S; Lockerman EL; Fujita N; Nishio M; Harris JL; Shaw AT; Engelman JA
    Cancer Discov; 2014 Jun; 4(6):662-673. PubMed ID: 24675041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer.
    Vijayvergia N; Mehra R
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):437-46. PubMed ID: 25135623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
    Sgambato A; Casaluce F; Maione P; Gridelli C
    Expert Rev Anticancer Ther; 2018 Jan; 18(1):71-80. PubMed ID: 29187012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.
    Katayama R; Friboulet L; Koike S; Lockerman EL; Khan TM; Gainor JF; Iafrate AJ; Takeuchi K; Taiji M; Okuno Y; Fujita N; Engelman JA; Shaw AT
    Clin Cancer Res; 2014 Nov; 20(22):5686-96. PubMed ID: 25228534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.
    Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
    Curr Clin Pharmacol; 2016; 11(2):77-87. PubMed ID: 27138017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
    Croegaert K; Kolesar JM
    Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice.
    Caccese M; Ferrara R; Pilotto S; Carbognin L; Grizzi G; Caliò A; Brunelli M; Cuppone F; Petraglia S; Scarpa A; Tortora G; Bria E
    Expert Opin Pharmacother; 2016 Dec; 17(17):2253-2266. PubMed ID: 27682212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?
    Toyokawa G; Seto T
    Clin Lung Cancer; 2014 Sep; 15(5):313-9. PubMed ID: 24984564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.
    Ou SH
    Drug Des Devel Ther; 2011; 5():471-85. PubMed ID: 22162641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.
    Karachaliou N; Santarpia M; Gonzalez Cao M; Teixido C; Sosa AE; Berenguer J; Rodriguez Capote A; Altavilla G; Rosell R
    Expert Opin Investig Drugs; 2017 Jun; 26(6):713-722. PubMed ID: 28463570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
    EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions.
    Cameron L; Solomon B
    Drugs; 2015 Jul; 75(10):1059-70. PubMed ID: 26076736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ALK inhibitors in non-small cell lung cancer: the latest evidence and developments.
    Sullivan I; Planchard D
    Ther Adv Med Oncol; 2016 Jan; 8(1):32-47. PubMed ID: 26753004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL; Wenger SD; Kim M; Thompson LA
    Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ; Shapiro GI
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance.
    Chen Z; Akbay E; Mikse O; Tupper T; Cheng K; Wang Y; Tan X; Altabef A; Woo SA; Chen L; Reibel JB; Janne PA; Sharpless NE; Engelman JA; Shapiro GI; Kung AL; Wong KK
    Clin Cancer Res; 2014 Mar; 20(5):1204-1211. PubMed ID: 24327273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer.
    Li S; Qi X; Huang Y; Liu D; Zhou F; Zhou C
    Clin Lung Cancer; 2015 Mar; 16(2):86-91. PubMed ID: 25458559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race.
    de Castro-Carpeño J; Perona R; Belda-Iniesta C
    Clin Transl Oncol; 2011 Nov; 13(11):774-9. PubMed ID: 22082640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.